Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson’s disease

被引：2
|
作者：
Ilona Joniec-Maciejak
Adriana Wawer
Danuta Turzyńska
Alicja Sobolewska
Piotr Maciejak
Janusz Szyndler
Dagmara Mirowska-Guzel
Adam Płaźnik
机构：
[1] Medical University of Warsaw,Department of Experimental and Clinical Pharmacology
[2] Centre for Preclinical Research and Technology (CePT),Department of Neurochemistry
[3] Institute of Psychiatry and Neurology,undefined
来源：
Pharmacological Reports | 2018年 / 70卷
关键词：
Parkinson’s disease; Octanoic acid; MPTP; PGC-1α; PEPCK;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：988 / 992
页数：4
相关论文
共 50 条
  • [41] The MPTP model of Parkinson's disease
    Smeyne, RJ
    Jackson-Lewis, V
    MOLECULAR BRAIN RESEARCH, 2005, 134 (01): : 57 - 66
  • [42] Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes
    Du, Ren-Wei
    Bu, Wen-Guang
    NEUROIMMUNOMODULATION, 2021, 28 (02) : 82 - 89
  • [43] Rotigotine prevents neurodegeneration in a mouse model of Parkinson's disease
    Stichel, C. C.
    Scheller, D. K. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 108 - 108
  • [44] Role of the RET/GDNF signaling pathway in protection of the nigro-striatal system in a MPTP mouse model for Parkinson's disease
    Drinkut, A.
    Nagel, F.
    Kramer, E. R.
    Kuegler, S.
    Schulz, J. B.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 49 - 50
  • [45] L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease
    King, Jennifer M.
    Muthian, Gladson
    Mackey, Veronica
    Smith, Marquitta
    Charlton, Clivel
    LIFE SCIENCES, 2011, 89 (17-18) : 638 - 643
  • [46] ROLE OF THE RET/GDNF SIGNALING PATHWAY IN PROTECTION OF THE NIGRO-STRIATAL SYSTEM IN A MPTP MOUSE MODEL FOR PARKINSON'S DISEASE
    Drinkut, A.
    Kramer, E. R.
    Schulz, J. B.
    Kuegler, S.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 256 - 256
  • [47] Paroxetine prevents loss of nigral dopaminergic neurons in the MPTP model of Parkinson's disease
    Chung, Y. C.
    Kim, S. R.
    Noh, J. S.
    Chung, Y. K.
    Jin, B. K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S127 - S127
  • [48] Characterization of the Striatal Extracellular Matrix in a Mouse Model of Parkinson's Disease
    Freitas, Ana
    Aroso, Miguel
    Barros, Antonio
    Fernandez, Miriam
    Conde-Sousa, Eduardo
    Leite, Marina
    Carvalho, Eva Daniela
    Ribeiro, Cristina C.
    Ferreira, Rita
    Pego, Ana Paula
    Vitorino, Rui
    Gomez-Lazaro, Maria
    ANTIOXIDANTS, 2021, 10 (07)
  • [49] Fenofibrate has a disease modifier effect in the MPTP mouse model of Parkinson's disease
    Kreisler, Alexandre
    Duhamel, Alain
    Destee, Alain
    Bordet, Regis
    NEUROLOGY, 2008, 70 (11) : A283 - A283
  • [50] Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
    Liu, WeiZhen
    Li, Yanwei
    Jalewa, Jaishree
    Saunders-Wood, Taylor
    Li, Lin
    Hoelscher, Christian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 765 : 284 - 290
12345